@article{10.11648/j.ajlm.20200501.13,
  author = {Rimaz Elhag Gurashi and Moawia Elsadig Hummeida and Faisal Galal Abdelaziz},
  title = {Diagnostic Value of Serum Biomarker Human Epididymis Protein4 in Ovarian Cancers},
  journal = {American Journal of Laboratory Medicine},
  volume = {5},
  number = {1},
  pages = {18-27},
  doi = {10.11648/j.ajlm.20200501.13},
  url = {https://doi.org/10.11648/j.ajlm.20200501.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20200501.13},
  abstract = {Ovarian cancer is the fifth most common cancer affecting women today. In fact, ovarian cancer is responsible for more deaths than any other type of female reproductive cancer. According to the American Cancer Society, 20,000 women are diagnosed with ovarian cancer each year. Since diagnosis early on is associated with improved rates of survival, an effective screening strategy that detects early stage ovarian cancer may have a significant impact on mortality from the disease. Cancer researchers are under way to develop more accurate tumor markers that can be used to identify disease in its early stages, to predict the effectiveness of treatment, or to predict the chance of cancer recurrence after treatment has ended. Cancer antigen 125 (CA125) is an established biomarker for ovarian cancer detection. As CA125 effectiveness in the identification of the malignancy is threatened by its low diagnostic specificity, measurements of other tumor marker, Human epididymis protein4 (He4), in the serum have been proposed for improving the sensitivity and specificity of laboratory identification of the disease. The aim of our research study was to evaluate the diagnostic performance of Human epididymis protein4 (He4) in ovarian cancer patients. Our study group consisted of 90 Sudanese ladies age range (16-80) years old attending Gynological Oncology clinics in Omdurman Military hospitals. Blood samples were collected and centrifugated using standardized procedure, all analyses were performed in serum samples. Human epididymis protein 4 (HE4) serum concentration were determined using Enzyme-Linked Immunosorbent Assay (CUSABIO ELISA kits) for the quantitative invitro diagnostic measurement. the data were treated Statistically. The study results shown that epithelial ovarian cancer is the most common ovarian cancer type in Sudan followed by germ cell tumors. Serum level of Human epididymis protein 4 (HE4) biomarker within the reference range in the control group. In contrast, increasing serum level of Human epididymis protein 4 (HE4) were obtained in the ovarian cancer patients, A general agreement that a combination of multiple biomarkers may increase diagnostic sensitivity and specificity over use of individual marker. The results of this study confirmed that, by combining He4 measurements with cancer antigen 125, we can improve the diagnostics performance for OC. HE4 is a relatively stable serum biomarker for ovarian cancer with a higher diagnostic prediction.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Diagnostic Value of Serum Biomarker Human Epididymis Protein4 in Ovarian Cancers
AU  - Rimaz Elhag Gurashi
AU  - Moawia Elsadig Hummeida
AU  - Faisal Galal Abdelaziz
Y1  - 2020/01/17
PY  - 2020
N1  - https://doi.org/10.11648/j.ajlm.20200501.13
DO  - 10.11648/j.ajlm.20200501.13
T2  - American Journal of Laboratory Medicine
JF  - American Journal of Laboratory Medicine
JO  - American Journal of Laboratory Medicine
SP  - 18
EP  - 27
PB  - Science Publishing Group
SN  - 2575-386X
UR  - https://doi.org/10.11648/j.ajlm.20200501.13
AB  - Ovarian cancer is the fifth most common cancer affecting women today. In fact, ovarian cancer is responsible for more deaths than any other type of female reproductive cancer. According to the American Cancer Society, 20,000 women are diagnosed with ovarian cancer each year. Since diagnosis early on is associated with improved rates of survival, an effective screening strategy that detects early stage ovarian cancer may have a significant impact on mortality from the disease. Cancer researchers are under way to develop more accurate tumor markers that can be used to identify disease in its early stages, to predict the effectiveness of treatment, or to predict the chance of cancer recurrence after treatment has ended. Cancer antigen 125 (CA125) is an established biomarker for ovarian cancer detection. As CA125 effectiveness in the identification of the malignancy is threatened by its low diagnostic specificity, measurements of other tumor marker, Human epididymis protein4 (He4), in the serum have been proposed for improving the sensitivity and specificity of laboratory identification of the disease. The aim of our research study was to evaluate the diagnostic performance of Human epididymis protein4 (He4) in ovarian cancer patients. Our study group consisted of 90 Sudanese ladies age range (16-80) years old attending Gynological Oncology clinics in Omdurman Military hospitals. Blood samples were collected and centrifugated using standardized procedure, all analyses were performed in serum samples. Human epididymis protein 4 (HE4) serum concentration were determined using Enzyme-Linked Immunosorbent Assay (CUSABIO ELISA kits) for the quantitative invitro diagnostic measurement. the data were treated Statistically. The study results shown that epithelial ovarian cancer is the most common ovarian cancer type in Sudan followed by germ cell tumors. Serum level of Human epididymis protein 4 (HE4) biomarker within the reference range in the control group. In contrast, increasing serum level of Human epididymis protein 4 (HE4) were obtained in the ovarian cancer patients, A general agreement that a combination of multiple biomarkers may increase diagnostic sensitivity and specificity over use of individual marker. The results of this study confirmed that, by combining He4 measurements with cancer antigen 125, we can improve the diagnostics performance for OC. HE4 is a relatively stable serum biomarker for ovarian cancer with a higher diagnostic prediction.
VL  - 5
IS  - 1
ER  - 

Copy | Download